XNASLFCR
Market cap268mUSD
Dec 27, Last price
7.28USD
1D
-2.80%
1Q
47.07%
Jan 2017
-47.25%
Name
Lifecore Biomedical Inc
Chart & Performance
Profile
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑05 | 2023‑05 | 2022‑05 | 2021‑05 | 2020‑05 | 2019‑05 | 2018‑05 | 2017‑05 | 2016‑05 | 2015‑05 | |
Income | ||||||||||
Revenues | 128,261 24.20% | 103,269 -44.42% | 185,786 -65.86% | |||||||
Cost of revenue | 94,986 | 127,235 | 185,705 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 33,275 | (23,966) | 81 | |||||||
NOPBT Margin | 25.94% | 0.04% | ||||||||
Operating Taxes | 183 | 301 | (5,839) | |||||||
Tax Rate | 0.55% | |||||||||
NOPAT | 33,092 | (24,267) | 5,920 | |||||||
Net income | 12,013 -111.76% | (102,190) 121.75% | (46,084) 41.08% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 572 | 4,822 | (789) | |||||||
BB yield | -0.28% | -2.03% | 0.27% | |||||||
Debt | ||||||||||
Debt current | 4,906 | 1,850 | 45,625 | |||||||
Long-term debt | 134,531 | 121,753 | 122,475 | |||||||
Deferred revenue | 4,703 | 103,745 | ||||||||
Other long-term liabilities | 30,486 | 104,392 | 190 | |||||||
Net debt | 130,975 | 116,562 | 177,045 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (217) | (34,458) | (24,399) | |||||||
CAPEX | (17,921) | (20,763) | (28,134) | |||||||
Cash from investing activities | (17,921) | (4,153) | 81,768 | |||||||
Cash from financing activities | 7,509 | 39,700 | (57,021) | |||||||
FCF | 15,873 | 30,881 | 56,759 | |||||||
Balance | ||||||||||
Cash | 8,462 | 19,091 | 1,643 | |||||||
Long term investments | (12,050) | (10,588) | ||||||||
Excess cash | 2,049 | 1,878 | ||||||||
Stockholders' equity | (123,906) | (176,191) | (59,215) | |||||||
Invested Capital | 343,357 | 389,474 | 320,633 | |||||||
ROIC | 9.03% | 1.62% | ||||||||
ROCE | 13.88% | 0.03% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 36,658 | 29,958 | 29,466 | |||||||
Price | 5.62 -29.22% | 7.94 -19.55% | 9.87 -17.54% | |||||||
Market cap | 206,018 -13.39% | 237,867 -18.21% | 290,829 -17.06% | |||||||
EV | 379,580 | 393,674 | 467,874 | |||||||
EBITDA | 42,134 | (10,458) | 17,869 | |||||||
EV/EBITDA | 9.01 | 26.18 | ||||||||
Interest | 18,090 | 18,184 | 17,261 | |||||||
Interest/NOPBT | 54.37% | 21,309.88% |